Lupitux Injection contains Cetuximab 100 mg, a chimeric monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR). It is indicated for the treatment of patients with metastatic colorectal cancer and head and neck squamous cell carcinoma, particularly those with EGFR-expressing tumors. Cetuximab binds to the extracellular domain of EGFR, inhibiting ligand-induced receptor phosphorylation and subsequent activation of downstream signaling pathways involved in tumor cell proliferation, angiogenesis, and survival. Administration of Lupitux Injection is by intravenous infusion under the supervision of a qualified healthcare professional experienced in cancer therapy. Prior to initiation, patients should be tested for KRAS mutation status, as efficacy is primarily observed in those with wild-type KRAS tumors. Common adverse reactions include infusion-related reactions, dermatologic toxicities such as acneiform rash, and electrolyte imbalances, notably hypomagnesemia. Close monitoring during and after infusion is essential to manage potential hypersensitivity reactions. Dose modifications or discontinuation may be required based on toxicity severity. Lupitux Injection should be used in combination with chemotherapy regimens as per approved guidelines. Proper patient selection and adherence to recommended dosing schedules optimize therapeutic outcomes while minimizing risks associated with cetuximab therapy.